Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Vascular Endothelial Growth Factor A
  • Venous Thromboembolism

abstract

  • The addition of bevacizumab to chemotherapy did not statistically significantly increase the risk of VTEs versus chemotherapy alone. The risk for VTEs is driven predominantly by tumor and host factors.

publication date

  • May 2011

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.32.3220

PubMed ID

  • 21422411

Additional Document Info

start page

  • 1757

end page

  • 64

volume

  • 29

number

  • 13